Baxter International Valuation
Is BAX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BAX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BAX * (MX$687.31) is trading above our estimate of fair value (MX$388.22)
Significantly Below Fair Value: BAX * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BAX *?
Other financial metrics that can be useful for relative valuation.
What is BAX *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$20.70b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.2x |
Enterprise Value/EBITDA | 11.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BAX *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.1x | ||
STE STERIS | 3.8x | 5.2% | US$20.1b |
4543 Terumo | 4.5x | 5.9% | JP¥4.0t |
STMN Straumann Holding | 8.1x | 9.8% | CHF22.1b |
SOON Sonova Holding | 4.2x | 6.8% | CHF15.4b |
BAX * Baxter International | 1.4x | 3.6% | Mex$20.4b |
Price-To-Sales vs Peers: BAX * is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (5.4x).
Price to Earnings Ratio vs Industry
How does BAX *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Sales vs Industry: BAX * is good value based on its Price-To-Sales Ratio (1.4x) compared to the Global Medical Equipment industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is BAX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.4x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BAX *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$784.18 0% | 15.7% | Mex$1,108.43 | Mex$645.21 | n/a | 15 |
Apr ’25 | n/a | Mex$800.68 0% | 16.1% | Mex$1,136.56 | Mex$661.58 | n/a | 15 |
Mar ’25 | n/a | Mex$801.34 0% | 16.7% | Mex$1,145.58 | Mex$666.83 | n/a | 15 |
Feb ’25 | n/a | Mex$770.50 0% | 18.5% | Mex$1,150.84 | Mex$601.18 | n/a | 14 |
Jan ’25 | n/a | Mex$776.71 0% | 19.6% | Mex$1,165.69 | Mex$608.94 | n/a | 14 |
Dec ’24 | n/a | Mex$797.99 0% | 19.0% | Mex$1,175.06 | Mex$613.84 | n/a | 14 |
Nov ’24 | n/a | Mex$861.57 0% | 19.1% | Mex$1,208.00 | Mex$594.98 | n/a | 14 |
Oct ’24 | n/a | Mex$888.29 0% | 11.1% | Mex$1,159.39 | Mex$761.39 | n/a | 15 |
Sep ’24 | n/a | Mex$867.26 0% | 10.8% | Mex$1,133.78 | Mex$744.57 | n/a | 16 |
Aug ’24 | Mex$750.00 | Mex$860.24 +14.7% | 10.5% | Mex$1,121.87 | Mex$736.75 | n/a | 16 |
Jul ’24 | n/a | Mex$911.69 0% | 10.1% | Mex$1,183.21 | Mex$794.69 | n/a | 16 |
Jun ’24 | n/a | Mex$911.69 0% | 10.1% | Mex$1,183.21 | Mex$794.69 | n/a | 16 |
May ’24 | n/a | Mex$926.56 0% | 10.4% | Mex$1,204.65 | Mex$809.10 | n/a | 15 |
Apr ’24 | n/a | Mex$878.65 0% | 15.3% | Mex$1,212.64 | Mex$723.96 | n/a | 15 |
Mar ’24 | Mex$725.00 | Mex$913.15 +26.0% | 15.4% | Mex$1,250.05 | Mex$746.30 | n/a | 14 |
Feb ’24 | Mex$850.00 | Mex$1,139.80 +34.1% | 15.2% | Mex$1,595.35 | Mex$957.21 | n/a | 14 |
Jan ’24 | n/a | Mex$1,244.27 0% | 13.2% | Mex$1,683.45 | Mex$1,010.07 | n/a | 16 |
Dec ’23 | Mex$1,769.50 | Mex$1,287.23 -27.3% | 11.3% | Mex$1,673.00 | Mex$1,043.17 | n/a | 15 |
Nov ’23 | Mex$1,769.50 | Mex$1,303.92 -26.3% | 10.4% | Mex$1,682.69 | Mex$1,148.19 | n/a | 15 |
Oct ’23 | Mex$1,769.50 | Mex$1,430.93 -19.1% | 8.7% | Mex$1,739.47 | Mex$1,227.86 | n/a | 13 |
Sep ’23 | Mex$1,769.50 | Mex$1,430.93 -19.1% | 8.7% | Mex$1,739.47 | Mex$1,227.86 | n/a | 13 |
Aug ’23 | Mex$1,769.50 | Mex$1,441.00 -18.6% | 7.6% | Mex$1,732.65 | Mex$1,284.20 | Mex$750.00 | 13 |
Jul ’23 | Mex$1,769.50 | Mex$1,685.78 -4.7% | 9.9% | Mex$1,965.22 | Mex$1,389.55 | n/a | 13 |
Jun ’23 | Mex$1,769.50 | Mex$1,775.62 +0.3% | 8.8% | Mex$2,088.14 | Mex$1,392.09 | n/a | 14 |
May ’23 | n/a | Mex$1,887.12 0% | 8.1% | Mex$2,142.91 | Mex$1,571.47 | n/a | 15 |
Apr ’23 | n/a | Mex$1,986.16 0% | 5.1% | Mex$2,163.91 | Mex$1,813.57 | n/a | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.